RxDoctor Payments Data

Amanda Lanceleve

Addiction Medicine · Haverhill, MANPI 1053037424

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 28.6% of the total.

$1,568in general payments, 2019–2025

Across 71 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$449
  • Neurocrine Biosciences, Inc.$275
  • Alkermes, Inc.$211
  • Otsuka America Pharmaceutical, Inc.$176
  • Lundbeck LLC$110
  • E.r. Squibb & Sons, L.L.C.$103
  • plus $244 from 6 others

What the payments were for

  • Food & beverage$1,568100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,568 in reported general payments places this provider in the 80th percentile of 57 addiction medicine providers in Massachusetts.

See all addiction medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$31,000
Medicare patients
73
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl62$129,183
RexultiBrexpiprazole29$85,311
CaplytaLumateperone Tosylate13$21,257
Quetiapine Fumarate197$3,767
Clonazepam301$2,752
Perphenazine65$2,593
Aripiprazole50$2,488
Trazodone Hcl205$2,481
Oxcarbazepine58$2,427
Venlafaxine Hcl ErVenlafaxine Hcl67$2,099
Lamotrigine137$1,900
Ziprasidone Hcl26$1,840
Mirtazapine89$1,781
Lorazepam182$1,697
Clozapine58$1,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$40$129,18362 claims
Otsuka America Pharmaceutical, Inc.Rexulti$176$85,31129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 57 addiction medicine providers in Massachusetts.

Other addiction medicine in Haverhill

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →